File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Hepatitis B Surface Antigen Loss in Antiviral-treated Patients with HBeAg(+) Chronic Hepatits B (CHB) Infection: Observations from Antiviral-naive Patients Treated with Entecavir (ETV) or lamivudine (LVD)

TitleHepatitis B Surface Antigen Loss in Antiviral-treated Patients with HBeAg(+) Chronic Hepatits B (CHB) Infection: Observations from Antiviral-naive Patients Treated with Entecavir (ETV) or lamivudine (LVD)
Authors
Issue Date2006
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
Citation
The 57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, USA, 27-31 October 2006. In Hepatology, 2006, v. 44 n. Suppl 1, p. 558A, abstract no. 992 How to Cite?
AbstractBackground: Hepatitis B surface antigen (HBsAg) loss and HBsAg seroconversion are considered an important goal of HBV therapy but are seldom achieved with current treatments. We describe baseline characteristics and Wk 24 treatment responses of patients who demonstrated confirmed HBsAg loss by Wk 120 (on-treatment or during the 24-week follow-up period). Methods: A total of 709 nucleosidenaı ¨ve, HBeAg( ) patients received ETV 0.5 mg (n 354) or LVD 100 mg (n 355) once daily for a minimum of 52 Wks and maximum of 96 Wks in the randomized, double-blind ETV-022 trial. Entry criteria included: biopsy-confirmed liver disease, serum HBV DNA by bDNA levels 3 MEq/mL, ALT levels 1.3-10 x ULN and no prior nucleoside therapy 12 Wks. Serum HBV DNA, HBV serology (HBeAg/anti-HBe) and ALT were measured on treatment and through 24 weeks off-treatment . Results: HBsAg loss was confirmed in 28/709 (4%) patients (18 for ETV and 10 for LVD) by Wk 120. Baseline characteristics and Wk 24 treatment responses for patients with confirmed HBsAg loss by Wk 120 are presented below. Conclusions: Patients with confirmed HBsAg loss by Wk 120 were characterized by genotype A or D, male sex and Caucasian race at baseline and by HBeAg loss and HBeAg seroconversion at Wk 24.
Persistent Identifierhttp://hdl.handle.net/10722/102352
ISSN
2015 Impact Factor: 11.711
2015 SCImago Journal Rankings: 4.752

 

DC FieldValueLanguage
dc.contributor.authorGish, Ren_HK
dc.contributor.authorChang, TTen_HK
dc.contributor.authorLai, CLen_HK
dc.contributor.authorde Man, Ren_HK
dc.contributor.authorGadano, Aen_HK
dc.contributor.authorPoordad, Fen_HK
dc.contributor.authorZhu, Jen_HK
dc.contributor.authorYang, Jen_HK
dc.contributor.authorBrett-Smith, Hen_HK
dc.date.accessioned2010-09-25T20:27:11Z-
dc.date.available2010-09-25T20:27:11Z-
dc.date.issued2006en_HK
dc.identifier.citationThe 57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, USA, 27-31 October 2006. In Hepatology, 2006, v. 44 n. Suppl 1, p. 558A, abstract no. 992en_HK
dc.identifier.issn0270-9139en_HK
dc.identifier.urihttp://hdl.handle.net/10722/102352-
dc.description.abstractBackground: Hepatitis B surface antigen (HBsAg) loss and HBsAg seroconversion are considered an important goal of HBV therapy but are seldom achieved with current treatments. We describe baseline characteristics and Wk 24 treatment responses of patients who demonstrated confirmed HBsAg loss by Wk 120 (on-treatment or during the 24-week follow-up period). Methods: A total of 709 nucleosidenaı ¨ve, HBeAg( ) patients received ETV 0.5 mg (n 354) or LVD 100 mg (n 355) once daily for a minimum of 52 Wks and maximum of 96 Wks in the randomized, double-blind ETV-022 trial. Entry criteria included: biopsy-confirmed liver disease, serum HBV DNA by bDNA levels 3 MEq/mL, ALT levels 1.3-10 x ULN and no prior nucleoside therapy 12 Wks. Serum HBV DNA, HBV serology (HBeAg/anti-HBe) and ALT were measured on treatment and through 24 weeks off-treatment . Results: HBsAg loss was confirmed in 28/709 (4%) patients (18 for ETV and 10 for LVD) by Wk 120. Baseline characteristics and Wk 24 treatment responses for patients with confirmed HBsAg loss by Wk 120 are presented below. Conclusions: Patients with confirmed HBsAg loss by Wk 120 were characterized by genotype A or D, male sex and Caucasian race at baseline and by HBeAg loss and HBeAg seroconversion at Wk 24.-
dc.languageengen_HK
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/en_HK
dc.relation.ispartofHepatologyen_HK
dc.rightsHepatology. Copyright © John Wiley & Sons, Inc.en_HK
dc.titleHepatitis B Surface Antigen Loss in Antiviral-treated Patients with HBeAg(+) Chronic Hepatits B (CHB) Infection: Observations from Antiviral-naive Patients Treated with Entecavir (ETV) or lamivudine (LVD)en_HK
dc.typeConference_Paperen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0270-9139&volume=44&issue=Suppl 1&spage=992&epage=&date=2006&atitle=Hepatitis+B+Surface+Antigen+Loss+in+Antiviral-treated+Patients+with+HBeAg(+)+Chronic+Hepatits+B+(CHB)+Infection:+Observations+from+Antiviral-naive+Patients+Treated+with+Entecavir+(ETV)+or+lamivudine+(LVD)en_HK
dc.identifier.emailLai, CL: hrmelcl@hku.hken_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.identifier.doi10.1002/hep.21398-
dc.identifier.hkuros133893-
dc.identifier.volume44en_HK
dc.identifier.issueSuppl 1en_HK
dc.identifier.spage558Aen_HK
dc.identifier.epage558A-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats